University Cancer Research Fund
The University Cancer Research Fund (UCRF) is a nation-leading investment to stimulate cancer research and reduce North Carolina’s leading cause of death. The Fund builds upon the exceptional research base at UNC Lineberger Comprehensive Cancer Center, the state’s only public, NCI-designated comprehensive cancer center.
UCRF’s Goal
To create a nation-leading cancer research effort and to reduce North Carolina’s cancer burden. UCRF is accomplishing these goals through:
- Discovery to better understand the causes and course of cancer.
- Innovation to create new and better ways to prevent, diagnose and treat cancer.
- Delivery of improved cancer care, screening and prevention across the state.
Latest News
-
Study points the way to boosting immunotherapy effectiveness against breast cancer and other solid tumors
CAR-T therapy has proven effective for some blood cancers. New research by Jonathan S. Serody, MD, and colleagues suggests ways to use it effectively to attack solid tumors.
-
UNC Lineberger partners with Fort Bragg to tackle tobacco use
A strategic partnership with Kurt Ribisl, PhD, and colleagues is helping the nation’s largest Army base rework its tobacco policies and take steps to improve the health of its soldiers and their families.
-
Study illustrates how obesity-related comorbidities may contribute to mortality gap between Black and white women with early breast cancer
Kirsten Nyrop, PhD, and colleagues found Black women with early breast cancer had higher rates of obesity and other health conditions that can affect outcomes, compared with white women.
-
Therapy using immune system cells preserves vision in mice implanted with rare eye cancer
Zongchao Han, MD, PhD, Barbara Savoldo, MD, PhD, and colleagues report in Nature Cancer they used a combination of CAR-Ts and interleukin (IL)-15 to treat retinoblastoma in a mouse model.
-
New vulnerability found in lung squamous cancer may facilitate drug targeting at the cellular level
New research by Chad Pecot, MD, and colleagues shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer.